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Abstract
Purpose of Review Dairy products contain both beneficial and harmful nutrients in relation to cardiometabolic diseases. Here, we
provide the latest scientific evidence regarding the relationship between dairy products and cardiometabolic diseases by
reviewing the literature and updating meta-analyses of observational studies.
Recent Findings We updated our previous meta-analyses of cohort studies on type 2 diabetes, coronary heart disease (CHD), and
stroke with nine studies and confirmed previous results. Total dairy and low-fat dairy (per 200 g/d) were inversely associated with
a 3–4% lower risk of diabetes. Yogurt was non-linearly inversely associated with diabetes (RR = 0.86, 95%CI: 0.83–0.90 at 80 g/
d). Total dairy and milk were not associated with CHD (RR~1.0). An increment of 200 g of daily milk intake was associated with
an 8% lower risk of stroke.
Summary The latest scientific evidence confirmed neutral or beneficial associations between dairy products and risk of cardio-
metabolic diseases.
Keywords Dairy products . Cardiometabolic . Type 2 diabetes . Coronary heart disease . Stroke
Abbreviations
BMI Body mass index
CHD Coronary heart disease
CI Confidence interval
GLST Generalized least-square trend
MFGM Milk fat globule membranes
RCT Randomized controlled trial
RR Relative risk
SFA Saturated fatty acids
Introduction
Diet-related cardiometabolic diseases such as type 2 diabetes
mellitus, coronary heart disease (CHD), and stroke result in a
large global health burden, accounting for over 17 million
deaths in 2010 [1•]. Recent data from 195 countries showed
that dietary factors have become very important risk factors
contributing to worldwide deaths [2•, 3]. It is imperative that
the clinical and scientific community identifies modifiable
factors that can help to prevent or mitigate these cardiometa-
bolic diseases. Specific foods and overall dietary patterns,
rather than single isolated nutrients, are most relevant for
chronic disease [4].
Dairy products are worldwide increasingly consumed as
indicated by recent tabulations by the International Dairy
Federation. From 2006 to 2013, global steep increases in per
capita dairy product consumption were found. Especially,
Asia, Africa, and Latin America are growing markets for dairy
consumption (Fig. 1) [5].
The potential role for dairy products as part of a healthy diet
was recognized by several guidelines of Western as well as
Asian countries [6–9]. For example, in the US, three daily
servings of dairy, mainly low-fat or fat-free, are recommended
[7]. In the Netherlands, based on the 2015 food based dietary
guidelines [10], daily portions of low-fat and sugar-free milk,
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yogurt, and cheese are recommended to fit in a balanced
healthy diet [11]. The Chinese and Japanese recommendations
are 300 ml of daily dairy [8] and two daily servings of milk
and dairy products, respectively [9].
Dairy products such as milk, cheese, and yogurt are
nutrient-dense as described in Table 1 for the main nutrient
contents in these products according to the Dutch Food
Composition Tables (www.rivm.nl/nevo). Of note, full-fat
milk, still contains considerably less fat than low-fat cheese
per 100 g product. Cheese contains 50% less water than milk
and is therefore more nutrient dense than milk or yogurt.
Cheese is relatively high in saturated fat, with low-fat cheese
containing 8 g more fat than low-fat milk or yogurt per 100 g
product. Dairy contains not only various nutrients beneficial
for cardiometabolic health such as calcium, potassium, phos-
phorus, different vitamins such as B2, B12, D and K2, but also
harmful nutrients such as sodium, saturated fat, and added
sugars [12]. Vitamin D levels of dairy vary between countries
depending on fortification. There has been a controversy in
the literature over whether dairy products have a prominent
role in healthy diets, with alternating more or less focus on
beneficial or harmful nutrients [13–15].
Besides high nutrient and energy densities, dairy is hetero-
geneous comprising many products. For example, butter is a
type of dairy, yet it is often grouped with fats and oils because
of the role butter has in the diet. Initially in scientific research
milk and total dairy, including a variety of products, were
grouped together and as such compared between studies
[16–18]. In different studies, various definitions of total dairy
were used, including differences in (amounts of) combined
products, which makes comparisons on associations of dairy
with chronic disease complex. A recent shift was made over
the past 5 years, with research focusing on teasing out differ-
ent dairy products by type (milk, cheese, yogurt), fermentation
and fat-content (low- and full-fat dairy and milk).
Fig. 1 Per capita Milk Consumption from 2006 to 2012. (Available at
https://slideplayer.com/slide/11662620/). From CNIEL/IDF, FAO Food
Outlook, PRB [5], with kind permission
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Many reviews and meta-analyses summarizing associa-
tions between dairy products and cardiometabolic diseases
were published in the past 20 years [17–20, 21•, 22, 23••,
24••, 25••]. Dairy products as specific foods have received
increased attention, with controversies and confusion about
whether or not to consume more dairy products or more spe-
cific dairy products, such as cheese, yogurt, or milk [23••,
24••, 25••, 26, 27].
This review provides the latest scientific evidence on dairy
products in relation to cardiometabolic diseases (type 2 diabe-
tes, CHD, and stroke). In addition to reviewing a large range
of meta-analyses of prospective cohort studies, we identified
recent cohort studies to update our previous meta-analyses on
dairy in relation to type 2 diabetes, CHD, and stroke [23••,
24••, 25••].
Methods
Literature Search and Selection
Search syntaxes were similar to our previous meta-analyses
[23••, 24••, 25••]. Published articles, without language restric-
tions, up to July 2018 were retrieved from PubMed
complemented by hand searches of reference lists of recent
reviews and meta-analyses. Eligible studies were selected
using predefined criteria, i.e., prospective design and reported
data on dairy consumption in relation to type 2 diabetes, CHD,
and stroke. We excluded studies on animals, children aged <
18 years, and patient populations. Our previous meta-analyses
were updated with nine studies [28–36]. The publication of
Talaei 2017-II [36] was used to update the CHD results. The
previous stroke meta-analysis already contained the
(unpublished) data of that study.
Data Extraction
We extracted descriptive study data as well as ranges of intake,
medians or midpoints, numbers of subjects and stroke events,
person-years at risk, and relative risks (RRs) with the corre-
sponding 95% CIs for each category of dairy intake. Portion
sizes of dairy products to convert these into grams per day,
were generally reported in the included studies. If dairy intake
was only reported in servings, without the actual portion size,
we used portion sizes of 177 g for total, low-fat, and full-fat
dairy; 244 g for total, low-fat and full-fat milk; 244 g for
yogurt; and 43 g for cheese to estimate grams per day. These
were mainly UK- [37] and US- [38] based portion sizes for
dairy products. For open-ended upper limits of intake, we
applied the same width as the adjacent category, whereas for
open-ended lowest categories a zero was assigned.
Statistical Analysis
We performed meta-analyses for type 2 diabetes on total dairy,
low-fat dairy, and yogurt, for CHD on total dairy and milk,
and for stroke on total dairy, milk, full- and low-fat dairy, for
which the most interesting findings were reported in our pre-
viously published meta-analyses [23••, 24••, 25••]. Analyses
for cheese intake and risk of stroke were not updated due to
lack of new studies. If studies presented several statistical
models, we included the model that included most con-
founders. Linearity of associations was investigated using
spline analysis and dose-response meta-regression
(Generalized Least-Square Trend; GLST). Splined variables
were created using MKSPLINE in STATA in order to select
the most appropriate knot points of nonlinear associations
based on goodness-of-fit tests and Chi-square statistics.
Linear and nonlinear associations were further analyzed using
dose-response (GLST) meta-regression analysis. Random-
effects meta-regression trend estimation of summarized
dose-response data [39] was used to derive the incremental
dose-response RRs. Forest plots were created for linear
dose-response slopes per 200 g/d for total, low-fat, and full-
fat dairy and total milk. The shape of the associations within
individual studies was visualized by means of Ding’s spaghet-
ti plots, as described previously [40]. Between-study hetero-
geneity was assessed by the Cochrane Q test with an I2 statis-
tic [41]. Statistical analyses were performed using STATA
version 11.0 (StataCorp, College Station, TX, USA).
Results
An overview of all recent reviews and meta-analyses, and
prospective cohort studies is summarized in Supplementary
Table 1. In the following sections, these reviews and updated
meta-analyses are presented for type 2 diabetes, CHD, and
stroke.
Dairy and Diabetes, Evidence from Prospective Cohort
Studies
The evidence on the association between dairy products and
type 2 diabetes from meta-analyses was summarized recently
by Drouin-Chartier et al. [42••] and Yu and Hu [43••]. Drouin-
Chartier et al. [42••] summarizedmeta-analyses (including our
work) reporting associations between various dairy products
and type 2 diabetes (Fig. 2). Our work [23••] was rated as
reasonably high quality (73%) compared to the other meta-
analyses, according to the Meta-analysis of Observational
Study in Epidemiology checklist based on the Grading of
Recommendations Assessment, Development, and
Evaluation scale. Comparable meta-analyses on dairy prod-
ucts and incident diabetes published prior to ours were from
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Aune et al. [44], Gao et al. [45], Tong et al. [18], Elwood et al.
[17], and Chen et al. [46]. The results from all meta-analyses
showed consistently neutral or inverse associations for total
and low-fat dairy products, with the most striking inverse
association for yogurt and type 2 diabetes. Associations for
full-fat dairy, milk, and fermented dairy were consistently
neutral. The results for cheese, however, differed between
the meta-analyses, with an inverse association in the meta-
analyses by Aune et al. [44] and Gao et al. [45], but not by
Gijsbers et al. [23••], which was the most complete meta-
analysis.
The meta-analysis by Aune et al. [44] included eight
cheese-specific studies and the final pooled result was driven
mostly by the large EPIC-Interact study [47], whereas the
meta-analyses by Gijsbers [23••] included 12 cheese-specific
studies (13 population samples), including large cohorts like
the Nurses’ Health Study I and II, the Health Professionals
Follow-up Study, the Swedish Malmo Diet and Cancer study.
Gao et al. [45] did not show detailed analyses for cheese in a
figure and also included fewer cohort studies.
As indicated above, dairy has been the focus in a large
number of reviews and meta-analyses. Each one included a
different perspective on the topic, with different numbers of
studies included. Gijsbers et al. [23••] included 22 cohort stud-
ies. In a recent systematic review and meta-analysis by
Schwingshackl et al. [48], 21 cohort studies on dairy intake
with 44,474 type 2 diabetes cases were included, with a
different selection and number of studies when compared to
the meta-analysis by Gijsbers et al. Schwingshackl et al. [48]
included two studies [28, 49], which were not included in
Gijsbers et al., because one study [28] was published after the
publication by Gijsbers et al. [23••], and one was a cross-
sectional study [49]. Schwingshackl et al. [48] published more
recently than our work, omitted for unknown reasons some
prospective cohort studies which were included by Gijsbers
et al. [50–52]. Similar inverse associations were reported by
Schwingshackl et al. compared with Gijsbers et al. for total
dairy. Each additional daily intake of 200 g of dairy products
was inversely associated with diabetes risk (RR: 0.97; 95%
Confidence Interval (CI) 0.94–0.99, I2 = 74%, n = 21 studies).
In subgroup analyses, the inverse association with total dairy
and diabetes was observed only in Asian and Australian studies
(RR = 0.84, 95% CI 0.71–1.01), but not for American and
European studies (RR = 0.98, 95% CI 0.95–1.01). This was
also observed by Gijsbers et al. [23••]. Moreover, significant
associations were observed by Schwingshackl et al. [48] for
studies with < 1000 type 2 diabetes cases, participants ≥
50 years of age, and a shorter follow-up (< 10 years). In sub-
group analyses, low-fat dairy products showed a borderline
inverse association, whereas no association could be observed
for full-fat dairy products [48]. In another recent meta-analysis
by Tian et al. [53], a smaller number of studies (11 cohort
studies) was summarized for total dairy, full-fat milk, and yo-
gurt results (high vs low dose), with inverse associations of
0.89 (95% CI 0.84–0.94), 0.87 (95%CI: 0.78–0.96), and 0.83
(95%CI: 0.70–0.98), respectively. These results seemed inflat-
ed compared to other meta-analyses, especially for full-fat
milk, but several cohort studies were missing [46, 54, 55] and
duplicate results were used [56, 57].
Updated Meta-Analyses on Dairy and Diabetes
Our previous work (Gijsbers et al.) was the most complete
meta-analysis so far, and included 22 prospective cohort
studies comprising 579,832 individuals and 43,118 type 2
diabetes cases [23••]. In summary, we found that total dairy
was significantly linearly associated with a 3% lower risk of
diabetes per 200 g/d, low-fat dairy was borderline signifi-
cantly associated with a 4% lower risk per 200 g/d, and
yogurt had the most striking result with a non-linear inverse
significant association with diabetes (up to 15% lower risk).
No associations with full-fat dairy, fermented dairy, milk,
and cheese were found. In all meta-analyses by Gijsbers
et al., considerable significant unexplained heterogeneity
was present (I2 = 66% for total dairy, 68% for low-fat dairy,
73% for yogurt, all p values < 0.05). In subgroup analyses,
we found a stronger inverse association for total dairy and
total milk consumption in Asian populations (13–15% low-
er risk, although not statistically significant), compared to a
null association in European populations. This may have
Fig. 2 Summary of meta-analyses on dairy products and risk of type 2
diabetes byDrouin-Chartier [42••]. FromDrouin-Chartier JP, Brassard D,
Tessier-Grenier M, Cote JA, Labonte ME, Desroches S, et al. Systematic
Review of the Association between Dairy Product Consumption and Risk
of Cardiovascular-Related Clinical Outcomes. Adv Nutr. 2016;7
[6]:1026–40, by permission of Oxford University Press
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been due to confounding adjustments (less extensive in the
Asian cohorts than in the European cohorts). We updated
our meta-analyses for type 2 diabetes with four cohort stud-
ies [28–30, 58] for the major findings in Gijsbers et al.
[23••] and similar results were found (Table 2). In total,
26 cohort studies were included. Total dairy (per 200 g/d)
was borderline significantly associated with a 3% lower
risk of diabetes, and low-fat dairy was also borderline sig-
nificantly associated with a 4% lower risk of diabetes (I2 =
60%) (Supplementary Fig. 1 forest plot low-fat dairy).
Yogurt had the most striking result, with a non-linear in-
verse significant association with diabetes (RR = 0.86,
95%CI 0.83–0.90, p < 0.001, I2 = 69%, at 80 g/d compared
with 0 g/d) (Fig. 3 Ding’s spline plot yogurt). In all these
meta-analyses, considerable heterogeneity was present.
Dairy and Coronary Heart Disease, Evidence
from Prospective Cohort Studies
In recent years, several meta-analyses or reviews of meta-
analyses have published results on dairy intake or specific
types of dairy and CHD [25••, 26, 42••, 59•, 60•, 61, 62].
Drouin-Chartier et al. (2016) summarized meta-analyses
reporting associations between dairy products and CHD
[42••]. They concluded that, based on moderate to high-
quality evidence, total dairy, full-fat dairy, low-fat dairy, milk,
cheese, and yogurt consumption showed no association with
the risk of CHD. Our later meta-analysis by Guo et al. [25••]
Table 2 New results from dose-response meta-analyses (linear and non-linear) on relationships between dairy products, type 2 diabetes, coronary heart
disease, and stroke
Dairy type (increment g/d) New studies N studies
(samples)
RR (95% CI) Heterogeneity
I2(%), P
N events; total N Knot, P nonlinearity
RR (95% CI) at knot
Diabetes mellitus
Total dairy (200) Hruby 2017 [29],
Brouwer-Brolsma
2016 [28], Talaei 2018 [31],
Virtanen 2017 [30]
20 (21) 0.97 (0.95–1.00) 62.8, p < 0.001 46,905;
5,741,718
Linear
Low-fat dairy (200) Hruby 2017 [29],
Brouwer-Brolsma
2016 [28]
15 (16) 0.96 (0.92–1.00) 60.3, p < 0.001 28,531;
5,313,782
Linear
Yogurt (100) Hruby 2017 [29],
Brouwer-Brolsma
2016 [28]
13 (14) 0.94 (0.91–0.97) 68.6, p < 0.001 37,223;
5,184,590
Non-linear 80 g/day
p < 0.0001, 0.86
(0.83–0.90)
CHD
Total dairy (200) Buckland 2009 [34],
Dilis 2012 [35],
Talaei Singapore 2017 [36]
14 (16) 1.00 (0.98–1.03) 40.2, 0.049 11,445;
3,216,346
Linear
Milk (200) Talaei Iran 2017 [33] 12 (13) 1.01 (0.97–1.04) 40.9, 0.061 9176;
2,231,651
Linear
Stroke
Total dairy (200) Haring 2015 [32] 10 0.98 (0.96–1.01) 65.6, 0.002 11,647;
2,725,832
Linear
Low-fat dairy (200) Haring 2015 [32] 7 (9) 0.97 (0.95–0.99) 0.0, p = 0.68 11,092;
4,097,631
Non-linear 75 g/day,
p = 0.007)
0.94 (0.89–1.002)
Full-fat dairy (200) Haring 2015 [32] 6 (7) 0.96 (0.93–0.99) 0.0, p = 0.90 10,038;
4,076,849
Non-linear 55 g/day,
p = 0.03
0.96 (0.90–1.01)
Milk (200) Talaei Iran 2017 [33] 15 (17) 0.92 (0.88–0.97) 85.2, p < 0.001 25,377;
4,381,604
125 g/day, p < 0.0001
0.86 (0.83–0.89)
Fig. 3 Ding’s Spaghetti plot for yogurt intake and risk of type 2 diabetes
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was in line with those results, as well as with the meta-analysis
by Bechthold et al. [59•]. Drouin-Chartier noted that associa-
tions between fermented dairy and CHD remain uncertain
because of limited evidence of sufficient quality [25••, 42••].
In 2017, Gille et al. [60•] concluded that there is moderate
evidence for an inverse association with CHD with the con-
sumption of cheese based on three meta-analyses [26, 61, 62].
Guo et al. [25••] observed a moderate inverse association be-
tween fermented dairy and CVD and all-cause mortality, but
not with CHD. Another recent meta-analysis with a focus only
on total dairy [59•] confirmed neutral associations with CHD.
Updated Meta-Analyses on Dairy and CHD
We updated our previous meta-analyses for total dairy and
milk in relation to CHD [25••] with four cohort studies. In
total, 15 cohort studies were included. Total dairy was not
associated with incident CHD (Table 2). The results for milk
also remained unchanged with RRs (95%CI) per 200 g/day of
1.01 (0.96–1.06) in our previous publication [25••] and 1.01
(95%CI 0.97–1.04) in the updated meta-analysis
(Supplementary Fig. 2).
Dairy and Stroke, Evidence from Prospective Cohort
Studies
In recent years, several meta-analyses or reviews of meta-
analyses have published results on dairy intake or specific
types of dairy and incident stroke [24••, 26, 42••, 43••, 59•,
61, 63••]. In 2011, we observed a non-significant inverse as-
sociation of milk with stroke risk with a RR of 0.87 (95% CI:
0.72–1.07) per 200 ml of daily intake in a meta-analysis based
on six cohort studies with large heterogeneity [21•]. In a later
meta-analysis by Hu et al. of dairy consumption and stroke
risk, the pooled RR was 0.91 (95% CI 0.82–1.01) for high vs.
low milk intake with large heterogeneity, based on nine stud-
ies. The association was nonlinear [64].
In 2016, we pooled 18 prospective cohort studies from 11
countries with 8 to 26 years of follow-up that included
762,414 individuals and almost 30,000 stroke events based
on a search up to October 2015 [24••]. An increment of
200 g of daily milk intake was associated with a 7% lower
risk of stroke (RR = 0.93; 95% CI 0.88–0.98; P = 0.004; I2 =
86%). RRs were 0.82 (95% CI 0.75–0.90) in East Asian and
0.98 (95% CI 0.95–1.01) in Western countries (median in-
takes 38 and 266 g/day, respectively) with less but still con-
siderable heterogeneity within the continents. Cheese intake
was marginally inversely associated with stroke risk (RR =
0.97; 95% CI 0.94–1.01 per 40 g/day). Risk reductions were
maximal around 125 g/day for milk and from 25 g/day on-
wards for cheese. Based on a limited number of studies, full-
fat milk (n = 4 studies) was directly associated with increased
stroke risk, whereas full-fat total dairy (n = 6), as well as low-
fat dairy (n = 7) was inversely associated.
The meta-analysis by Chen et al. [26], focused on cheese
and no other dairy subtypes in relation to CVD, CHD, and
stroke. The meta-analysis included studies until December
2015 and data largely overlapped with our meta-analysis with
some minor differences: one Dutch study was missing [65]
and for one other Dutch study [66] other results were used
[67]. The summary RR for an increment of 40 g/d of cheese
consumption was 0.94 (95% CI 0.84–1.04) for stroke risk
(I2 = 64%). The largest risk reduction was observed at approx-
imately 40 g/d. This non-linear association was also observed
in our meta-analysis [24••], although in our analyses the risk
reduction was maximal from 25 g per day of cheese onwards.
Drouin-Chartier et al. (2016) summarized meta-analyses
(not including ours) on various dairy products and stroke
[42••]. Three meta-analyses [61, 62, 64] concluded that total
dairy was inversely associated with stroke, whereas we report-
ed (nine studies) neutral associations [24••], which were con-
firmed by the most recent meta-analysis including 12 cohort
studies by Bechthold et al. [59•] (RR per 200 g/d total dairy:
0.98, 0.96–1.00; I2: 50%; n = 11).
In line with our findings [24••], Drouin-Chartier et al. also
found that milk and cheese were associated with a lower risk
of stroke in several meta-analyses, with variations in quality of
the meta-analyses [42••].
Yu and Hu [43••] presented in 2018 summaries of recent
meta-analyses on dairy and dairy fat intake and cardiometa-
bolic diseases confirming our findings on associations be-
tween dairy, cheese, milk, and yogurt with stroke incidence.
New Cohort Studies
Since our previous meta-analysis [24••], new studies have been
published [32, 33, 36, 67]. We updated our previous finding by
adding two new cohorts [32, 33], one with data for total, low-
fat, and full-fat dairy [32] and one with data on full-fat milk
[33]. Results of Praagman et al. [67] were (partly) overlapping
with already included data of Dalmeijer et al. [66], which we
therefore retained. The results from Talaei 2017 based on the
Singapore Chinese Health Study [36] had already been includ-
ed as unpublished results in our meta-analysis. Because those
data were based on adjustments as requested by our group, we
retained those results. For all four exposures, the results
remained largely unchanged (Table 2). An increment of 200 g
of daily milk intake was associated with an 8% lower risk of
stroke (RR: 0.92; 95% CI 0.88–0.97; I2 = 85%). RRs were 0.82
(95%CI 0.75–0.89) in East Asian and 0.98 (95%CI 0.95–1.01)
in Western countries (median intakes 38 and 266 g/day, respec-
tively) (Fig. 4). Risk reductions were maximal around 125 g/
day for milk (Supplementary Fig. 3). All milk results were
similar to our previous findings [24••]. In the new studies, no
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new data on cheese was presented, so these results were as
presented previously.
Conclusion and Discussion
Scientific evidence from prospective cohort studies to date has
suggested null or (weak) inverse associations between dairy
intake and risk of type 2 diabetes, CHD, and stroke. This
review, adding nine new cohort studies to existing meta-anal-
yses, further confirmed these associations. These results
should be placed in the context of observed and unexplained
heterogeneity. We presented robust findings in line with pre-
vious meta-analyses [23••, 24••, 25••] and reviews.
Some differences between meta-analyses [23••, 44, 45]
were reported though, even when the analyses covered the
same time period of publications. These differences could be
caused by different approaches (dose-response analyses ver-
sus comparing high vs. low intakes), by the categorization of
studies in the various dairy type categories, or by whether or
not specific studies were omitted.
Just before finalizing this review, the PURE cohort in-
vestigators published dairy data in relation to 9-year inci-
dent all-cause mortality, major CVD events, and (fatal and
non-fatal) stroke in 21 countries from five continents
(136,384 individuals) [68]. This international perspective
is an important contribution to the field. Overall, dairy
consumption was associated with a lower risk of mortality
and major cardiovascular events, especially stroke, but no
association was found with myocardial infarction. Milk
and yogurt intake were inversely associated with all-
cause mortality and major CVD events; results for milk
in relation to stroke were not provided. Diabetes was not
included as an outcome. Associations were consistent for
regions with either low or high dairy intakes. The (strong)
inverse associations of total dairy with all-cause, CVD, and
stroke of the PURE study were not observed in our previ-
ous dose-response meta-analyses [24••, 25••]. It is not yet
clear which types of dairy were driving the associations of
the PURE study. The PURE study was still underpowered
to examine the effects of specific dairy types within each
region for the various outcomes, but the follow-up and
population are still being expanded.
Fig. 4 Forest plot for milk intake and risk of stroke, stratified by continent
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We and others described potential mechanisms previously
[23••, 24••]. Regarding the association between yogurt and
diabetes, probiotic bacteria, which have been reported to low-
er blood cholesterol, or potential effects onmicrobiota [69, 70]
could possibly play a role. With respect to the association
between milk and stroke, minerals such as calcium and potas-
sium have been previously shown to lower blood pressure [71,
72]. Differential effects for full and low-fat yogurt or milk
could not be detected.
The current discussions and confusion on health effects of
fatty acids have contributed to a shift of thinking from a
nutrient-based approach towards a food-based approach.
Dietary guidelines traditionally mainly focused on saturated
fat in dairy products and its low-density lipoprotein raising
effects [6]. However, the link between food sources of satu-
rated fat and CHD is more complicated because food sources
of saturated fat contain an array of saturated and unsaturated
fatty acids, each of which may differentially affect lipoprotein
metabolism, as well as contribute significant amounts of other
nutrients, which may alter CHD risk. Recent evidence showed
more beneficial associations with cardiometabolic disease for
saturated fatty acids (SFA) from dairy products than SFA from
meat [73••, 74]. Furthermore, the food matrix may be impor-
tant. A meta-analysis of randomized clinical trials (RCTs)
studying the effect of cheese consumption on blood lipids
and lipoproteins found that cheese caused lower total choles-
terol, low-density lipoprotein cholesterol, and high-density
lipoprotein cholesterol concentrations compared with butter,
despite a similar SFA/polyunsaturated fatty acid ratio [75•].
Butter is the most SFA dense food (50% SFA). It does not
contain milk fat globule membranes (MFGM), as opposed to
other types of dairy. A recent RCT showed that, in contrast to
milk fat without MFGM, milk fat enclosed by MFGM does
not impair the lipoprotein profile [76]. A systematic review
and meta-analysis by Pimpin et al. (2016) focused specifically
on butter and cardiometabolic diseases [63••]. Based on four
studies including 11 country-specific cohorts mainly from
Europe with more than 200,000 participants and ~ 24,000
incident diabetes cases, butter was inversely associated with
type 2 diabetes (RR: 0.96; 95% CI: 0.93–0.99 per daily 14-g
serving). Butter was not associated with CHD or stroke.
However, a recent observational study in 71,410women, aged
50–79 years, showed that substituting butter with tub marga-
rine (teaspoon/day) was associated with a borderline lower
risk of myocardial infarction (HR = 0.95; 95% CI 0.89–1.00)
after a follow-up of 13 years [77], which is consistent with
what has been found for fatty acid substitution analyses [78].
The potential protective association of tub margarine may be
explained by its lower proportion of SFA, trans fatty acids, and
higher proportion of monounsaturated fatty acids and polyun-
saturated fatty acids, compared with butter.
All evidence of dairy in relation to disease endpoints has
been derived from observational studies, and residual
confounding remains an issue in this type of research. There
is evidence that milk and yogurt intake is related to healthy
behaviors [79] and further evidence on causality is warranted.
Also, the impact of dairy products per se on health cannot be
fully dissociated from that of the foods it replaces [79, 80].
This needs to be investigated further in the future.
To study causality, additional evidence from RCTs and
other types of designs such as Mendelian randomization stud-
ies are needed. Drouin-Chartier et al. carried out a comprehen-
sive narrative review on the effects of dairy foods, irrespective
of fat content, on cardiometabolic risk factors [81••]. That
review included a range of RCTs as well as the meta-
analyses of RCTs published by Benatar et al. [82] and De
Goede et al. [75•], and the systematic reviews of Turner
et al. [83] and Labonté et al. [84]. This paper [81••] was also
cited by Gille et al. [60•] in a very recent review on fermented
foods and cardiometabolic disease. RCTs, comparing high vs.
low dairy or dairy vs. other foods, suggested neutral or no
effects of dairy consumption on cardiometabolic risk factors,
including insulin resistance, lipids, blood pressure, inflamma-
tion, and vascular function [81••]. Currently, there are no
RCTs with dairy products as the main intervention with long
enough follow-up periods so that cardiometabolic disease
endpoints can be studied. Therefore, we are mostly relying
on data from observational studies in dietary guidelines
around the world. Results of short-term RCTs with effects
on cardiovascular risk factors were largely consistent with
large prospective cohort studies assessing associations be-
tween dairy products and cardiometabolic diseases as summa-
rized in this review. Ideally, well-designed RCTs with long-
term interventions are needed to confirm these effects on car-
diometabolic disease endpoints. The design of the control
group in future RCTs on dairy foods needs to be chosen care-
fully to ensure that foods consumed in replacement of dairy
reflect consumers’ choices and dietary habits. As described by
Drouin-Chartier et al. [81••] various foods used in the RCTs to
substitute dairy products in the control low-dairy or dairy-free
diets affect the results and interpretation and make direct com-
parison between RCTs difficult.
Mendelian randomization analyses have been more widely
used to assess potential causal estimates of environmental risk
factors with health outcomes. This type of analysis has the
advantage over observational studies of minimizing con-
founding by using genetic markers as instrumental variables
of environmental risk factors and therefore assessing causality.
A recent Mendelian randomization analysis [85•] using 22
observational studies with 197,332 participants examined the
causal effect of dairy consumption on systolic blood pressure
and risk of hypertension, to confirm previously found inverse
relationships between milk and hypertension [86]. There was
no association between genetically determined dairy intake
and systolic blood pressure or incident hypertension [85•,
87]. Similarly, Mendelian randomization studies found no
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associations betweenmilk and diabetes [88–90] and CHD [90,
91] which is in line with intake-based results for milk in rela-
tion to diabetes and CHD. The only associations reported from
Mendelian randomization studies were between genetically
determined milk intake and higher BMI [92, 93].
Interestingly, no Mendelian randomization study for milk in
relation to stroke has yet been performed. Lactase persistence
genes used in Mendelian randomization studies characterize
lactase containing dairy or milk intake, but not yogurt or
cheese. Most prominent results from meta-analyses on dairy
and diabetes, are found for yogurt intake and not milk or
cheese. To our knowledge, it is not possible for Mendelian
randomization studies to separate effects for milk, cheese,
and yogurt, highlighting areas for future research.
This systematic review showed neutral or beneficial as-
sociations between specific dairy products and risk of type
2 diabetes, CHD, and stroke. In updated meta-analyses,
higher milk intake was inversely associated with risk of
stroke, but not with risk of CHD or type 2 diabetes.
Stronger inverse associations for milk and stroke were
found in Asian vs. Western populations, but this has to be
investigated further with more Asian population samples.
Cheese was not related to diabetes, conflicting with some of
the earlier meta-analyses, depending on which studies were
included. Most striking results were found for yogurt and
type 2 diabetes, but this finding could also be due to more
healthy behaviors which are associated with yogurt con-
sumers [79]. Future epidemiological research should focus
on more careful consideration of confounding factors, and
replacement diets. Distinguishing between full and low-fat
cheese and yogurt, or milk and yogurt with or without
added sugars is not possible with the current literature.
Additional evidence from RCTs and other study designs
such as Mendelian Randomization studies should be inte-
grated with conventional epidemiological studies to inves-
tigate further mechanisms and causality.
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